Skip to main content
SpringerLink
Log in

The cost utility of adjuvant trastuzumab therapy for breast cancer appears more favourable in a Canadian population-based cohort

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Snow S, Skedgel C, Rayson D, Thompson K, Sellon M, Barnes P, Jeyakumar A, Younis T.Adjuvant trastuzumab for breast cancer outside of clinical trials: Cardiotoxicity and economic evaluation. 2009 Breast Cancer Symposium: abstr. 154, 08 Oct 2009. Available from: URL: http://www.asco.org

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

The cost utility of adjuvant trastuzumab therapy for breast cancer appears more favourable in a Canadian population-based cohort. Pharmacoecon. Outcomes News 591, 11 (2009). https://doi.org/10.2165/00151234-200905910-00026

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200905910-00026

Keywords

Search

Navigation